Market Cap
US$170.6b
Last Updated
2020/07/12 23:51 UTC
Data Sources
Company Financials +
Executive Summary
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Proven track record average dividend payer.
Similar Companies
Share Price & News
How has AbbVie's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.1%
ABBV
0.4%
US Biotechs
2.3%
US Market
1 Year Return
37.8%
ABBV
28.5%
US Biotechs
6.7%
US Market
Return vs Industry: ABBV exceeded the US Biotechs industry which returned 28.5% over the past year.
Return vs Market: ABBV exceeded the US Market which returned 6.7% over the past year.
Shareholder returns
| ABBV | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.1% | 0.4% | 2.3% |
| 30 Day | 4.7% | 10.8% | 7.4% |
| 90 Day | 20.6% | 24.0% | 17.9% |
| 1 Year | 43.8%37.8% | 29.8%28.5% | 9.0%6.7% |
| 3 Year | 50.6%32.4% | 31.7%27.4% | 36.6%27.7% |
| 5 Year | 69.7%38.3% | -5.3%-10.6% | 64.2%46.1% |
Price Volatility Vs. Market
How volatile is AbbVie's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
AbbVie (NYSE:ABBV) Could Be A Buy For Its Upcoming Dividend1 week ago | Simply Wall St
Read This Before Selling AbbVie Inc. (NYSE:ABBV) Shares4 weeks ago | Simply Wall St
A Look At The Fair Value Of AbbVie Inc. (NYSE:ABBV)Valuation
Is AbbVie undervalued compared to its fair value and its price relative to the market?
32.5%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABBV ($96.83) is trading below our estimate of fair value ($143.42)
Significantly Below Fair Value: ABBV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ABBV is good value based on its PE Ratio (17.1x) compared to the US Biotechs industry average (19.4x).
PE vs Market: ABBV is poor value based on its PE Ratio (17.1x) compared to the US market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: ABBV is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: ABBV has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
Next Steps
Future Growth
How is AbbVie forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
12.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABBV's forecast earnings growth (12.1% per year) is above the savings rate (2.2%).
Earnings vs Market: ABBV's earnings (12.1% per year) are forecast to grow slower than the US market (22.9% per year).
High Growth Earnings: ABBV's earnings are forecast to grow, but not significantly.
Revenue vs Market: ABBV's revenue (5.1% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: ABBV's revenue (5.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABBV's Return on Equity is forecast to be very high in 3 years time (86.3%).
Next Steps
Past Performance
How has AbbVie performed over the past 5 years?
11.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABBV has a large one-off loss of $3.7B impacting its March 31 2020 financial results.
Growing Profit Margin: ABBV's current net profit margins (24.6%) are higher than last year (16.3%).
Past Earnings Growth Analysis
Earnings Trend: ABBV's earnings have grown by 11.4% per year over the past 5 years.
Accelerating Growth: ABBV's earnings growth over the past year (57.9%) exceeds its 5-year average (11.4% per year).
Earnings vs Industry: ABBV earnings growth over the past year (57.9%) exceeded the Biotechs industry -4.5%.
Return on Equity
High ROE: ABBV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is AbbVie's financial position?
Financial Position Analysis
Short Term Liabilities: ABBV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ABBV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ABBV has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ABBV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: ABBV's debt is well covered by operating cash flow (21.2%).
Interest Coverage: ABBV's interest payments on its debt are well covered by EBIT (11.2x coverage).
Balance Sheet
Next Steps
Dividend
What is AbbVie current dividend yield, its reliability and sustainability?
4.87%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ABBV's dividend (4.87%) is higher than the bottom 25% of dividend payers in the US market (1.68%).
High Dividend: ABBV's dividend (4.87%) is in the top 25% of dividend payers in the US market (4.6%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, ABBV has been paying a dividend for less than 10 years.
Growing Dividend: ABBV's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (79.4%), ABBV's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ABBV's dividends in 3 years are forecast to be well covered by earnings (43.5% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Rick Gonzalez (66yo)
7.5yrs
Tenure
US$21,610,598
Compensation
Mr. Richard A. Gonzalez, also known as Rick, serves as the Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of  ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD21.61M) is above average for companies of similar size in the US market ($USD11.50M).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.5yrs | US$21.61m | 0.022% $37.3m | |
| Vice Chairman & President | 1.58yrs | US$9.51m | 0.0090% $15.3m | |
| Executive VP & CFO | 1.75yrs | US$8.77m | 0.0011% $2.0m | |
| Vice Chairman of External Affairs | 7.5yrs | US$15.14m | 0.012% $20.0m | |
| Vice Chairman & Chief Commercial Officer | no data | US$14.41m | 0.0088% $15.0m | |
| Executive Vice President of Operations | no data | no data | 0.0068% $11.6m | |
| Senior VP of Research & Development and Chief Scientific Officer | no data | no data | 0.0011% $1.9m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | no data | US$3.30m | no data | |
| VP of Scientific Affairs & Head of AbbVie Ventures | no data | no data | no data |
4.6yrs
Average Tenure
57yo
Average Age
Experienced Management: ABBV's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.5yrs | US$21.61m | 0.022% $37.3m | |
| Independent Director | 7.5yrs | US$333.43k | 0.0047% $8.1m | |
| Independent Director | 7.5yrs | US$319.95k | 0.000060% $102.4k | |
| Independent Director | 0.17yr | no data | 0.0072% $12.4m | |
| Lead Independent Director | 7.5yrs | US$387.75k | 0.00072% $1.2m | |
| Independent Director | 7.5yrs | US$352.03k | 0.00091% $1.6m | |
| Independent Director | 7.5yrs | US$333.71k | no data | |
| Independent Director | 7.5yrs | US$330.95k | 0.00011% $187.7k | |
| Independent Director | 4.5yrs | US$336.62k | no data | |
| Independent Director | 7.5yrs | US$375.10k | 0.0015% $2.5m |
7.5yrs
Average Tenure
66yo
Average Age
Experienced Board: ABBV's board of directors are considered experienced (7.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.
Top Shareholders
Company Information
AbbVie Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: AbbVie Inc.
- Ticker: ABBV
- Exchange: NYSE
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$170.648b
- Shares outstanding: 1.76b
- Website: https://www.abbvie.com
Number of Employees
Location
- AbbVie Inc.
- 1 North Waukegan Road
- North Chicago
- Illinois
- 60064
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ABBV * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Dec 2012 |
| ABBV | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Dec 2012 |
| 4AB | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Dec 2012 |
| 0QCV | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Dec 2012 |
| ABBV | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Dec 2012 |
| 4AB | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Dec 2012 |
| 4AB | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Dec 2012 |
| ABBV34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH REPR 1 COM USD0.01 | BR | BRL | Apr 2016 |
Biography
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/12 23:51 |
| End of Day Share Price | 2020/07/10 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.